|
1
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta j, et al European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamat AM, Hegarty PK, Gee JR, Clark PE,
Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ,
Lotan Y, et al: International Consultation on Urologic Disease -
European Association of Urology Consultation on Bladder Cancer
2012: ICUD-EAU International Consultation on Bladder Cancer 2012:
Screening, diagnosis, and molecular markers. Eur Urol. 63:4–15.
2013. View Article : Google Scholar
|
|
3
|
Cheng L, Davison DD, Adams J,
Lopez-Beltran A, Wang L, Montironi R and Zhang S: Biomarkers in
bladder cancer: Translational and clinical implications. Crit Rev
Oncol Hematol. 89:73–111. 2014. View Article : Google Scholar
|
|
4
|
Ushijima T: Detection and interpretation
of altered methylation patterns in cancer cells. Nat Rev Cancer.
5:223–231. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome - biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Besaratinia A, Cockburn M and Tommasi S:
Alterations of DNA methylome in human bladder cancer. Epigenetics.
8:1013–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim WJ and Kim YJ: Epigenetic biomarkers
in urothelial bladder cancer. Expert Rev Mol Diagn. 9:259–269.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC and
Kim WJ: Methy-lation of the RUNX3 promoter as a potential
prognostic marker for bladder tumor. J Urol. 180:1141–1145. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reinert T, Modin C, Castano FM, Lamy P,
Wojdacz TK, Hansen LL, Wiuf C, Borre M, Dyrskjøt L and Orntoft TF:
Comprehensive genome methylation analysis in bladder cancer:
Identification and validation of novel methylated genes and
application of these as urinary tumor markers. Clin Cancer Res.
17:5582–5592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sánchez-Carbayo M: Hypermethylation in
bladder cancer: Biological pathways and translational applications.
Tumour Biol. 33:347–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kandimalla R, van Tilborg AA and Zwarthoff
EC: DNA meth-ylation-based biomarkers in bladder cancer. Nat Rev
Urol. 10:327–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vinci S, Giannarini G, Selli C, Kuncova J,
Villari D, Valent F and Orlando C: Quantitative methylation
analysis of BCL2, hTERT, and DAPK promoters in urine sediment for
the detection of non-muscle-invasive urothelial carcinoma of the
bladder: A prospective, two-center validation study. Urol Oncol.
29:150–156. 2011. View Article : Google Scholar
|
|
13
|
Ibragimova I, Dulaimi E, Slifker MJ, Chen
DY, Uzzo RG and Cairns P: A global profile of gene promoter
methylation in treatment-naïve urothelial cancer. Epigenetics.
9:760–773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kalari S and Pfeifer GP: Identification of
driver and passenger DNA methylation in cancer by epigenomic
analysis. Adv Genet. 70:277–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim YJ, Yoon HY, Kim JS, Kang HW, Min BD,
Kim SK, Ha YS, Kim IY, Ryu KH, Lee SC, et al: HOXA9, ISL1 and
ALDH1A3 methylation patterns as prognostic markers for nonmuscle
invasive bladder cancer: Array-based DNA methylation and expression
profiling. Int J Cancer. 133:1135–1142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee JS, Leem SH, Lee SY, Kim SC, Park ES,
Kim SB, Kim SK, Kim YJ, Kim WJ and Chu IS: Expression signature of
E2F1 and its associated genes predict superficial to invasive
progression of bladder tumors. J Clin Oncol. 28:2660–2667. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS,
Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, et al: Predictive value
of progression-related gene classifier in primary non-muscle
invasive bladder cancer. Mol Cancer. 9:32010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Olkhov-Mitsel E and Bapat B: Strategies
for discovery and validation of methylated and hydroxymethylated
DNA biomarkers. Cancer Med. 1:237–260. 2012. View Article : Google Scholar
|
|
19
|
Castleman VH, Romio L, Chodhari R, Hirst
RA, de Castro SC, Parker KA, Ybot-Gonzalez P, Emes RD, Wilson SW,
Wallis C, et al: Mutations in radial spoke head protein genes RSPH9
and RSPH4A cause primary ciliary dyskinesia with
central-micro-tubular-pair abnormalities. Am J Hum Genet.
84:197–209. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Onoufriadis A, Shoemark A, Schmidts M,
Patel M, Jimenez G, Liu H, Thomas B, Dixon M, Hirst RA, Rutman A,
et al: Targeted NGS gene panel identifies mutations in RSPH1
causing primary ciliary dyskinesia and a common mechanism for
ciliary central pair agenesis due to radial spoke defects. Hum Mol
Genet. 23:3362–3374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ziętkiewicz E, Bukowy-Bieryłło Z, Voelkel
K, Klimek B, Dmeńska H, Pogorzelski A, Sulikowska-Rowińska A,
Rutkiewicz E and Witt M: Mutations in radial spoke head genes and
ultrastructural cilia defects in East-European cohort of primary
ciliary dyskinesia patients. PLoS One. 7:e336672012. View Article : Google Scholar
|
